Salix Pharmaceuticals Ltd (SLXP.OQ)

SLXP.OQ on NASDAQ Stock Exchange Global Select Market

117.20USD
19 Dec 2014
Price Change (% chg)

$-1.25 (-1.06%)
Prev Close
$118.45
Open
$118.54
Day's High
$120.40
Day's Low
$116.46
Volume
962,760
Avg. Vol
722,698
52-wk High
$172.97
52-wk Low
$86.00

SLXP.OQ

Chart for SLXP.OQ

About

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company’s products included... (more)

Overall

Beta: 0.87
Market Cap (Mil.): $7,468.37
Shares Outstanding (Mil.): 63.72
Dividend: --
Yield (%): --

Financials

  SLXP.OQ Industry Sector
P/E (TTM): -- 37.83 38.47
EPS (TTM): -1.27 -- --
ROI: -3.08 18.99 18.25
ROE: -12.75 19.75 19.13
Search Stocks

Exclusive: Paulson & Co takes stake in Salix on heels of inventory issues - sources

- Hedge fund Paulson & Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter.

18 Dec 2014

EXclusive: Paulson & Co takes stake in Salix on heels of inventory issues - sources

- Hedge fund Paulson & Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter.

18 Dec 2014

Salix to clear excess inventory earlier than expected

- Salix Pharmaceuticals Ltd said it would clear excess inventory by the end of 2015, a year earlier than it had forecast, sending its shares up about 6 percent premarket.

16 Dec 2014

UPDATE 1-Salix to clear excess inventory earlier than expected

Dec 16 - Salix Pharmaceuticals Ltd said it would clear excess inventory by the end of 2015, a year earlier than it had forecast, sending its shares up about 6 percent premarket.

16 Dec 2014

Salix to fix inventory pile-up by end of 2015

Dec 16 - Salix Pharmaceuticals Ltd said it would cut sales to wholesalers to fix an inventory issue related to three key drugs, and withdrew its forecast for the fourth quarter.

16 Dec 2014

US STOCKS-Wall St ends flat; healthcare off on new Obamacare challenge

* October jobs growth short of forecast but Aug, Sept revised up

07 Nov 2014

BRIEF-Pharming Group confirms receipt of $20 mln milestone payment from Salix Pharmaceuticals

* Pharming confirms receipt of $20 million milestone payment from Salix Pharmaceuticals

04 Nov 2014

Actavis to buy Durata in a deal valued at about $675 million

- Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

06 Oct 2014

UPDATE 3-Salix calls off inversion deal amid U.S. government crackdown

NEW YORK, Oct 3 - Salix Pharmaceuticals Ltd , citing a "changed political environment," said on Friday it had scrapped a deal with Italy's Cosmo Pharmaceuticals SpA that would have allowed it to shift its tax base from the United States to Europe.

03 Oct 2014

Fitch: Inversion Crackdown Breaks Salix-Cosmo; Others Move Ahead

(The following statement was released by the rating agency) NEW YORK, October 03 (Fitch) Tightened tax rules on U.S. companies seeking to re-domicile headquarters in countries with more favorable tax systems are pressuring some companies to reconsider that type of strategic move, according to Fitch Ratings. On Thursday October 2, Salix Pharmaceuticals (Salix) ended its $2.7 billion merger agreement with Cosmo Pharmaceuticals (Cosmo), saying a "changed political environment has created more

03 Oct 2014

Competitors

  Price Change
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,001 +73.50
Ranbaxy Laboratories Limited (RANB.NS) Rs615.45 -2.50
Nestle SA (NESN.VX) CHF72.25 +0.85
Pfizer Inc. (PFE.N) $31.94 +0.00
Abbott Laboratories (ABT.N) $46.31 +0.26
Bayer AG (BAYGn.DE) €115.40 +1.40
Bayer AG (BAYE.F) -- --
GlaxoSmithKline plc (GSK.L) 1,392.00p +13.50
Medtronic, Inc. (MDT.N) $75.07 +0.45
Shire PLC (SHP.L) 4,664.00p +35.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks